3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Thoracic
2
Gynecologic
2
Tumor-Agnostic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Gliosarcoma
12
Glioblastoma
12
Sarcoma
10
Central Nervous System Neoplasms
8
Astrocytoma
8
Brain Neoplasms
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, Non-Hodgkin
6
Lymphoma, Mantle-Cell
6
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, Follicular
6
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Burkitt Lymphoma
6
Recurrence
5
Oligodendroglioma
5
Hodgkin Disease
5
Glioma
5
Dendritic Cell Sarcoma, Interdigitating
5
Leukemia, Myeloid, Acute
4
Leukemia, Myeloid, Accelerated Phase
4
Leukemia
4
Familial ependymoma
4
Ependymoma
4
Rhabdomyosarcoma
3
Primary Myelofibrosis
3
Osteosarcoma
3
Neoplasm Metastasis
3
Interventions
Cyclophosphamide
17
pembrolizumab
12
Doxorubicin
10
fludarabine
7
Irinotecan
7
Blood Specimen Collection
7
Temozolomide
6
Gemcitabine
6
Etoposide
6
Radiotherapy
5
Ifosfamide
5
Carboplatin
5
Albumin-Bound Paclitaxel
5
tecogalan
4
cemiplimab
4
Vincristine
4
Trabectedin
4
Paclitaxel
4
Nivolumab
4
Filgrastim
4
Drug Therapy
4
Dexamethasone
4
Bevacizumab
4
pazopanib
3
olaparib
3
nilotinib
3
dostarlimab
3
aflibercept
3
Therapeutics
3
Taxes
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
sargramostim
×
Sarcoma
×
Clear all
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled